**
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Recursion Pharmaceuticals’s 8K filing here.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Articles
- Five stocks we like better than Recursion Pharmaceuticals
- What Are Some of the Best Large-Cap Stocks to Buy?
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- 3 Small Caps With Big Return Potential
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- How to Use Stock Screeners to Find Stocks
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
